Literature DB >> 20805728

Adjunctive psychotropic medications during electroconvulsive therapy in the treatment of depression, mania, and schizophrenia.

Roger F Haskett1, Colleen Loo.   

Abstract

Current guidelines regarding concomitant antidepressants during electroconvulsive therapy (ECT) are inconsistent. Although the American Psychiatric Association Task Force on ECT discouraged combination antidepressant treatment, owing to the minimal evidence for enhanced efficacy and concern about increased adverse effects, combination treatment is recommended and considered routine for many practitioners in the United States and other parts of the world. Considering the increasing levels of treatment resistance among patients referred for ECT and the high relapse rate after acute ECT, the role of concomitant antidepressant pharmacotherapy during ECT should be reevaluated. More research, however, is needed to explore the impact of administering specific antidepressants during acute and maintenance ECT (M-ECT), on antidepressant efficacy and cognitive adverse effects. This will require appropriately controlled studies of ECT medication combinations that include attention to a range of cognitive function measures and clinical response. In addition, the role of combination ECT and psychotropic medication in the treatment of mania and schizophrenia continues to receive attention, particularly in those patients who have shown inadequate responses to psychotropic medication alone. Although there is insufficient evidence to support the routine addition of antipsychotic medications to ECT during the treatment of acute mania, the literature suggests that it is unnecessary to discontinue antipsychotic medication when ECT is added to the treatment of a manic patient that has been unresponsive to pharmacological treatment. Despite the lack of well-controlled studies, the existing literature suggests that combination ECT and antipsychotic treatment is a useful option for patients with schizophrenia who are unresponsive to pharmacological interventions alone, and its adverse effect profile does not seem different from that seen with ECT alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805728      PMCID: PMC2952444          DOI: 10.1097/YCT.0b013e3181eee13f

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  44 in total

1.  Combined electroconvulsive-clozapine therapy.

Authors:  M Kupchik; B Spivak; R Mester; I Reznik; N Gonen; A Weizman; M Kotler
Journal:  Clin Neuropharmacol       Date:  2000 Jan-Feb       Impact factor: 1.592

2.  A CONTROLLED STUDY OF TREATMENTS OF DEPRESSION.

Authors:  I C WILSON; J T VERNON; M G SANDIFER; T GUIN
Journal:  J Neuropsychiatr       Date:  1963-06

3.  Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.

Authors:  Wai-Kwong Tang; Gabor S Ungvari
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-05       Impact factor: 5.067

4.  1. Nardil (phenelzine) as a potentiator of electroconvulsive therapy (E.C.T.). 2. A survey of outpatient E.C.T.

Authors:  D MULLER
Journal:  J Ment Sci       Date:  1961-11

5.  The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.

Authors:  Thomas C Baghai; Alain Marcuse; Melanie Brosch; Cornelius Schüle; Daniela Eser; Caroline Nothdurfter; Yvonne Steng; Ines Noack; Katrin Pietschmann; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  World J Biol Psychiatry       Date:  2006       Impact factor: 4.132

6.  Predictors of remission after electroconvulsive therapy in unipolar major depression.

Authors:  Alexandre Y Dombrovski; Benoit H Mulsant; Roger F Haskett; Joan Prudic; Amy E Begley; Harold A Sackeim
Journal:  J Clin Psychiatry       Date:  2005-08       Impact factor: 4.384

7.  Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).

Authors:  Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink
Journal:  Arch Gen Psychiatry       Date:  2006-12

8.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

9.  Efficacy and Safety of Combined ECT and Tricyclic Antidepressant Drugs in the Treatment of Depressed Geriatric Patients.

Authors:  John P. Nelson; Lloyd Benjamin
Journal:  Convuls Ther       Date:  1989

10.  Seizure activity in combined clozapine and ECT: a retrospective view.

Authors:  B A Cardwell; B Nakai
Journal:  Convuls Ther       Date:  1995-06
View more
  4 in total

1.  Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy.

Authors:  Cinara Ludvig Gonçalves; Helena Mendes Abelaira; Thayse Rosa; Airam Barbosa de Moura; Deise Cristina Veron; Laura Araújo Borba; Maria Eduarda Mendes Botelho; Mariana Pereira Goldim; Leandro Garbossa; Maria Eduarda Fileti; Fabricia Petronilho; Zuleide Maria Ignácio; João Quevedo; Gislaine Zilli Réus
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

2.  Electroconvulsive Therapy in Women: A Retrospective Study from a Mental Health Hospital in Turkey.

Authors:  Armağan Özdemir; Cana Aksoy Poyraz; Evrim Erten; Emre Çırakoğlu; Nesrin Tomruk
Journal:  Psychiatr Q       Date:  2016-12

3.  Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.

Authors:  Su-Hyuk Chi; Hyun-Ghang Jeong; Suji Lee; So-Young Oh; Seung-Hyun Kim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

4.  Accounting for symptom heterogeneity can improve neuroimaging models of antidepressant response after electroconvulsive therapy.

Authors:  Benjamin S C Wade; Gerhard Hellemann; Randall T Espinoza; Roger P Woods; Shantanu H Joshi; Ronny Redlich; Udo Dannlowski; Anders Jorgensen; Christopher C Abbott; Leif Oltedal; Katherine L Narr
Journal:  Hum Brain Mapp       Date:  2021-08-13       Impact factor: 5.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.